Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections | Zendy

Matteo Bassetti | Zendy; Ernestina Repetto | Zendy; Elda Righi | Zendy; Silvia Boni | Zendy; M. Diverio | Zendy; M.P. Molinari | Zendy; Michele Mussap | Zendy; Stefania Artioli | Zendy; Filippo Ansaldi | Zendy; Paolo Durando | Zendy; Giovanni Orengo | Zendy; F. Bobbio Pallavicini | Zendy; Claudio Viscoli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections

Author(s) -

Matteo Bassetti,

Ernestina Repetto,

Elda Righi,

Silvia Boni,

M. Diverio,

M.P. Molinari,

Michele Mussap,

Stefania Artioli,

Filippo Ansaldi,

Paolo Durando,

Giovanni Orengo,

F. Bobbio Pallavicini,

Claudio Viscoli

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm509

Subject(s) - colistin , acinetobacter baumannii , medicine , rifampicin , pneumonia , antibiotics , nephrotoxicity , carbapenem , incidence (geometry) , pseudomonas aeruginosa , tuberculosis , microbiology and biotechnology , toxicity , biology , bacteria , pathology , genetics , physics , optics

The increased incidence of nosocomial infections by multidrug-resistant organisms has motivated the re-introduction of colistin in combination with other antimicrobials in the treatment of infections. We describe the clinical and microbiological outcomes of patients infected with multidrug-resistant Acinetobacter baumannii who were treated with a combination of colistin and rifampicin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research